Detection, quantification, and characterization of potentially atherogenic triglyceride-rich remnant lipoproteins

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 19, Issue 10, 1999, Pages 2474-2486

  Cohn, Jeffrey S ^a   Marcoux, Caroline ^a   Davignon, Jean ^a  

^a CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

Author keywords

Apolipoproteins; Assay; Atherogenesis; Lipoproteins; Triglycerides

Indexed keywords

APOLIPOPROTEIN; TRIACYLGLYCEROL;

ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; HYPERTRIGLYCERIDEMIA; LIPID ANALYSIS; PARTICLE SIZE; PRIORITY JOURNAL;

EID: 0032858275     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.19.10.2474     Document Type: Article

References (185)

1. Gianturco SH, Bradley WA. Triglyceride-rich lipoproteins and their role in atherosclerosis. Curr Opin Lipidol. 1991;2:324-328.
2. Havel R. McCollum Award Lecture, 1993: triglyceride-rich lipoproteins and atherosclerosis: new perspectives. Am J Clin Nutr. 1994;59:795-759.
3. Krauss RM. Atherogenicity of triglyceride-rich lipoproteins. Am J Cardiol. 1998;81:13B-17B.
4. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA. 1993;269:3015-3023.
5. Davignon J, Conn JS. Triglycerides: a risk factor for coronary heart disease. Atherosclerosis. 1996;124:S57-S64.
6. Gotto AM. Triglyceride: the forgotten risk factor. Circulation. 1998; 97:1027-1028.
7. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk. 1996;3:213-219.
8. Hulley SB. Epidemiology as a guide to clinical decisions: the association between triglyceride and coronary heart disease. N Engl J Med. 1980;302:1383-1389.
9. Smith SJ, Cooper GR, Myers GL, Sampson EJ. Biological variability in concentrations of serum lipids: sources of variation among results from published studies and composite predicted values. Clin Chem. 1993;39:1012-1022.
10. Scheafer EJ, Levy RI, Anderson DW, Danner RN, Brewer HB Jr, Blackwelder WC. Plasma triglycerides in the regulation of HDL. Lancet. 1978;2:391-393.
11. Schonfeld G. Inherited disorders of lipid transport. Endocrinol Metab Clin North Am. 1990;19:229-257.
12. Mahley RW, Rail SC Jr. Type III hyperlipoproteinemia (dysbetalipoproteinemia): the role of apolipoprotein E in normal and abnormal lipoprotein metabolism. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic Basis of Inherited Disease. New York, NY: McGraw-Hill Publishing Co; 1989:1195-1213.
13. Nordestgaard BG, Nielsen LB. Atherosclerosis and arterial influx of lipoproteins. Curr Opin Lipidol. 1994;5:252-257.
14. Ji Z-S, Brecht WJ, Miranda RD, Hussain MM, Innerarity TL, Mahley RW. Role of heparan sulfate proteoglycans in the binding and uptake of apolipoprotein E-enriched remnant lipoproteins by cultured cells. J Biol Chem. 1993;268:10160-10167.
15. Evans AJ, Sawyez CG, Wolfe BM, Connelly PW, Maguire GF, Huff MW. Evidence that cholesteryl ester and triglyceride accumulation in J774 macrophages induced by very low density lipoprotein subfractions occurs by different mechanisms. J Lipid Res. 1993;34: 703-717.
16. Chung BH, Segrest JP, Smith K, Griffin FM, Brouillette CG. Lipolytic surface remnants of triglyceride-rich lipoproteins are cytotoxic to macrophages but not in the presence of high density lipoprotein: a possible mechanism of atherogenesis? J Clin Invest. 1989;83:1363-1374.
17. Rutledge JC, Woo MM, Rezai AA, Curtiss LK, Goldberg IJ. Lipoprotein lipase increases lipoprotein binding to the artery wall and increases endothelial layer permeability by formation of lipolysis products. Circ Res. 1997;80:819-828.
18. Mitropoulos KA, Miller GJ, Watts GF, Durrington PN. Lipolysis of triglyceride-rich lipoproteins activates coagulant factor XII: a study in familial lipoprotein-lipase deficiency. Atherosclerosis. 1992;95: 119-125.
19. Eisenberg S. Remnant lipoprotein metabolism. In: Crepaldi G, Tiengo A, Manzato E, eds. Diabetes, Obesity and Hyperlipidemia: V. The Plurimetabolic Syndrome. New York, NY: Elsevier Science Publishers; 1993:7-14.
20. Mjøs OD, Faergeman O, Hamilton RL, Havel RJ. Characterization of remnants produced during the metabolism of triglyceride-rich lipoproteins of blood plasma and intestinal lymph in the rat. J Clin Invest. 1975;56:603-615.
21. Pagnan A, Havel RJ, Kane JP, Kotite L. Characterization of human very low density lipoproteins containing two electrophoretic populations: double pre-beta lipoproteinemia and primary dysbetalipoproteinemia. J Lipid Res. 1977;18:613-622.
22. Cohn JS, Davignon J. Different approaches to the detection and quantification of triglyceride-rich lipoprotein remnants. In: Jacotot B, Mathé D, Fruchart JC, eds. Atherosclerosis XI. Singapore: Elsevier Science; 1998:771-776.
23. Lindgren FT, Jensen LC, Hatch FT. The isolation and quantitative analysis of serum lipoproteins. In: Nelson GJ, ed. Blood Lipids and Lipoproteins. New York, NY: John Wiley-Interscience; 1972: 181-274.
24. Mabuchi H, Tatami R, Ueda K, Ueda R, Haba T, Kametani T, Watanabe A, Wakasugi T, Ito S, Koizumi J, Ohta M, Miyamoto S, Takeda R. Serum lipid and lipoprotein levels in Japanese patients with familial hypercholesterolemia. Atherosclerosis. 1979;32: 435-444.
25. Avogaro P, Cazzolato G, Bittolo Bon G, Belussi F. Levels and chemical composition of HDL2, HDL3 and other major lipoprotein classes in survivors of myocardial infarction. Artery. 1979;5: 495-508.
26. Fontanais-Ferrer N, Serrat-Serrat J, Sorribas-Vivas A, Gonzalez-Garcia C, Gonzalez-Sastre F, Gomez-Gerique J. Quick method of determining lipoproteins, including those of intermediate density, in serum. Clin Chem. 1988;34:1753-1757.
27. Zhao S-P, Smelt AHM, Van den Maagdenberg AMJM, Van Tol A, Vroom TFFP, Gevers Leuven JA, Frants RR, Havekes LM, Van der Laarse A, Van't Hooft FM. Plasma lipoproteins in familial dysbetalipoproteinemia associated with apolipoproteins E2 (Arg158→Cys), E3-Leiden, and E2(Lys146→Gln), and effects of treatment with simvastatin. Arterioscler Thromb. 1994;14: 1705-1716.
28. Musliner TA, Giotas C, Krauss RM. Presence of multiple subpopulations of lipoproteins of intermediate density in normal subjects. Arteriosclerosis. 1986;6:79-87.
29. Reardon MF, Fidge NH, Nestel PJ. Catabolism of the very low density lipoprotein B apolipoprotein in man. J Clin Invest. 1978;61: 850-860.
30. Steiner G, Schwartz L, Shumak S, Poapst M. The association of increased levels of intermediate-density lipoproteins with smoking and with coronary artery disease. Circulation. 1987;75:124-130.
31. Mack WJ, Krauss RM, Hodis HN. Lipoprotein subclasses in the Monitored Atherosclerosis Regression Study (MARS): trealment effects and relation to coronary angiographic progression. Arterioscler Thromb Vasc Biol. 1996;16:697-704.
32. Gofman JW, Lindgren F, Elliott H, Mantz W, Hewitt J, Strisower B, Herring V, Lyon TP. The role of lipids and lipoproteins in atherosclerosis. Science. 1950;111:166-186.
33. Kameda K, Matsuzawa Y, Kubo M, Ishikawa K, Maejima I, Yamamura T, Yamamoto A, Tarui S. Increased frequency of lipoprotein disorders similar to type III hyperlipoproteinemia in survivors of myocardial infarction in Japan. Atherosclerosis. 1984; 51:241-249.
34. Tatami R, Mabuchi H, Ueda K, Ueda R, Haba T, Kametani T, Ito S, Koizumi J, Ohta M, Miyamoto S, Nakayama A, Kanaya H, Oiwake H, Genda A, Takeda R. Intermediate-density lipoprotein and cholesterol-rich very low density lipoprotein in angiographically determined coronary artery disease. Circulation. 1981;64: 1174-1184.
35. Reardon MF, Nestel PJ, Craig IH, Harper RW. Lipoprotein predictors of the severity of coronary artery disease in men and women. Circulation. 1985;71:881-888.
36. Krauss RM, Williams PT, Brensike J, Detre KM, Lindgren FT, Kelsey SF, Vranizan K, Levy RI. Intermediate-density lipoproteins and progression of coronary artery disease in hypercholesterolemic men. Lancet. 1987;1:62-66.
37. Watts GF, Mandalia S, Brunt JNH, Slavin BM, Coltart DJ, Lewis B. Independent associations between plasma lipoprotein subfraction levels and the course of coronary artery disease in the St. Thomas' Atherosclerosis Regression Study (STARS). Metabolism. 1993;42: 1461-1467.
38. Phillips NR, Waters D, Havel RJ. Plasma lipoproteins and progression of coronary artery disease evaluated by angiography and clinical events. Circulation. 1993;88:2762-2770.
39. Brensike JF, Levy RI, Kelsey SF. Effects of therapy with cholestyramine on progression of coronary arteriosclerosis: results of the NHLBI Type II Coronary Intervention Study. Circulation. 1984;69: 313-324.
40. Watts GF, Lewis B, Brunt JNH, Lewis ES, Coltart DJ, Smith LDR, Mann JI, Swan AV. Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St Thomas' Atherosclerosis Regression Study (STARS). Lancet. 1992;339:563-569.
41. Hodis HN, Mack WJ, Dunn M, Liu C, Liu C, Selzer RH, Krauss RM. Intermediate-density lipoproteins and progression of carotid arterial wall intima-media thickness. Circulation. 1997;5:2022-2026.
42. de Gennes JL, Dairou F, Hamon P, Truffert J. Ultracentrifugal evidence of a special subtype of mixed hyperlipidemia. Atherosclerosis. 1977;27:493-497.
43. Cohn JS, Giroux L-M, Fortin L-J, Davignon J. Prevalence of double pre-beta lipoproteinemia in hyperlipidemic patients is influenced by gender, menopausal status and apoE phenotype. Arterioscler Thromb Vasc Biol. 1997;17:2630-2637.
44. Morganroth J, Levy RI, Fredrickson DS. The biochemical, clinical, and genetic features of type III hyperlipoproteinemia. Ann Intern Med. 1975;82:150-157.
45. Kane JP, Chen GC, Hamilton RL, Hardman DA, Malloy MJ, Havel RJ. Remnants of lipoproteins of intestinal and hepatic origin in familial dysbetalipoproteinemia. Arteriosclerosis. 1983;3:47-56.
46. Hopkins PN, Wu LL, Schumacher MC, Emi M, Hegele RM, Hunt SC, Lalouel J-M, Williams RR. Type III dyslipoproteinemia in patients heterozygous for familial hypercholesterolemia and apolipoprotein E2: evidence for a gene-gene interaction. Arterioscler Thromb. 1991;11:1137-1146.
47. Dobmeyer J, Lohrmann J, Feussner G. Prevalence and association of atherosclerosis at three different arterial sites in patients with type III hyperlipoproteinemia. Atherosclerosis. 1996;119:89-98.
48. Mahley RW. Atherogenic hyperlipoproteinemia: the cellular and molecular biology of plasma lipoproteins altered by dietary fat and cholesterol. Med Clin North Am. 1982;66:375-402.
49. Bersot TP, Innerarity TL, Mahley RW, Havel RJ. Cholesteryl ester accumulation in mouse peritoneal macrophages induced by β-migrating very low density lipoproteins from patients with atypica dysbetalipoproteinemia. J Clin Invest. 1983;72:1024-1033.
50. Huff MW, Sawyez CG, Connelly PW, Maguire GF, Little JA, Hegele RA. β-VLDL in hepatic lipase deficiency induces apoE-mediated cholesterol ester accumulation in macrophages. Arterioscler Thromb. 1993;13:1282-1290.
51. Huff MW, Evans AJ, Sawyez CG, Wolfe BM, Nestel PJ. Cholesterol accumulation in J774 macrophages induced by triglyceride-rich lipoproteins: comparison of very low density lipoprotein from subjects with type III, IV, and V hyperlipoproteinemias. Arterioscler Thromb. 1991;11:221-233.
52. Sullivan PM, Mezdour H, Quarfordt SH, Maeda N. Type III hyperlipoproteinemia and spontaneous atherosclerosis in mice resulting from gene replacement of mouse Apoe with human APOE*2. J Clin Invest. 1998;102:130-135.
53. Huang Y, Schwender SW, Rall SC Jr, Sanan DA, Mahley RW. Apolipoprotein E2 transgenic rabbits: modulation of the type III hyperlipoproteinemic phenotype by estrogen and occurrence of spontaneous atherosclerosis. J Biol Chem. 1997;272:22685-22694.
54. Whitman SC, Miller DB, Wolfe BM, Hegele RA, Huff MW. Uptake of type III hypertriglyceridemic VLDL by macrophages is enhanced by oxidation, especially after remnant formation. Arterioscler Thromb Vasc Biol. 1997;17:1707-1715.
55. Mead MG, Dangerfield WG. The investigation of "mid-band" lipoproteins using polyacrylamide gel electrophoresis. Clin Chim Acta. 1974;51:173-182.
56. Tashiro J, Nishide T, Shinomiya M, Shirai K, Saito Y, Yoshida S, Yamashita M, Ohshima H, Murayama H, The "midband" lipoprotein is a coronary risk factor in Japanese patients with familial hypercholesterolaemia. Scand J Clin Lab Invest. 1993;53:335-338.
57. Yanagi K, Yamashita S, Kihara S, Nakamura T, Nozaki S, Nagai Y, Funahashi T, Kameda-Takemura K, Ueyama Y, Jiao S, Kubo M, Tokunaga K, Matsuzawa Y. Characteristics of coronary artery disease and lipoprotein abnormalities in patients with heterozygous familial hypercholesterolemia associated with diabetes mellitus or impaired glucose tolerance. Atherosclerosis. 1997;132:43-51.
58. Kawano M, Shinomiya M, Kanzaki T, Morisaki N, Shirai K, Saito Y, Yoshida S. Slow β-migrating lipoprotein: an atherogenic subclass of low density lipoproteins. Clin Biochem. 1996;29:241-248.
59. Hazard WR, Bierman EL, Delayed clearance of chylomicron remnants following vitamin A-containing oral fat loads in broad-beta disease (type III hyperlipoproteinemia). Metabolism. 1976;25. 777-801.
60. Berr F, Kern F Jr. Plasma clearance of chylomicrons labeled with retinol palmitate in healthy human subjects. J Lipid Res. 1984;25: 805-812.
61. Weintraub MS, Eisenberg S, Breslow JL. Different patterns of postprandial metabolism in normals and type IIa, type III and type IV hyperlipoproteinemics: effects of treatment with cholestyramine and gemfibrozil. J Clin Invest. 1987;79:1110-1119.
62. Weintraub MS, Eisenberg S, Breslow JL. Dietary fat clearance in normal subjects is regulated by genetic variation in apolipoprotein E. J Clin Invest. 1987;80:1571-1577.
63. Weintraub MS, Zechner R, Brown A, Eisenberg S, Breslow JL. Dietary polyunsaturated fats of W-6 and W-3 series reduce postprandial lipoprotein levels: chronic and acute effects of fat saturation on postprandial lipoprotein metabolism. J Clin Invest. 1988;82. 1884-1893.
64. Karpe F, Bell M, Bjorkegren J, Hamsten A. Quantification or postprandial triglyceride-rich lipoproteins in healthy men by retinyl ester labeling and simultaneous measurement of apolipoprotein B-48 and B-100. Arterioscler Thromb Vasc Biol. 1995;15:199-207.
65. Cohn JS, Johnson EJ, Millar JS, Cohn SD, Milne RW, Marcel YL, Russell RM, Schaefer EJ. Contribution of apoB-48 and apoB-100 triglyceride-rich lipoproteins (TRL) to postprandial increases in the plasma concentration of TRL triglycerides and retinyl esters. J Lipid Res. 1993;34:2033-2040.
66. Krasinski SD, Cohn JS, Russell RM, Schaefer EJ. Postprandial plasma vitamin A metabolism in humans: a reassessment of the use of plasma retinyl esters as markers for intestinally derived chylomicrons and their remnants. Metabolism. 1990;39:357-365.
67. Simpson HS, Williamson CM, Olivecrona T, Pringle S, Maclean J, Lorimer AR, Bonnefous F, Bogaievsky Y, Packard CJ, Shepherd J. Postprandial lipemia, fenofibrate and coronary artery disease. Atherosclerosis. 1990;85:193-202.
68. Groot PHE, Van Stiphoul WAHJ, Krauss XH, Jansen H, Van Tol A, Van Ramshorst E, Chin-On S, Hofman A, Cresswell SR, Havekes L. Postprandial lipoprotein metabolism in normolipidemic men with and without coronary artery disease. Arterioscler Thromb. 1991;11: 653-662.
69. Uiterwaal CSPM, Grobbee DE, Witteman JCM, van Stiphout W-AHJ, Krauss XH, Havekes LM, de Bruijn AM, van Tol A, Hofman A. Postprandial triglyceride response in young adult men and familial risk for coronary atherosclerosis. Ann Intern Med. 1994; 121:576-583.
70. Ginsberg HN, Jones J, Blaner WS, Thomas A, Karmally W, Fields L, Blood D, Begg MD. Association of postprandial triglyceride and retinyl palmitate resnonses with newly diagnosed exercise-induced myocardial ischemia in middle-aged men and women. Arterioscler Thromb Vasc Biol. 1995;15:1829-1838.
71. Sharrett AR, Chambless LE, Heiss G, Paton CC, Fatsch W, for the ARIC Investigators. Association of postprandial triglyceride and retinyl palmitate responses with asymptomatic carotid artery atherosclerosis in middle-aged men and women: the Atherosclerosis Risk in Communities (ARIC) Study. Arteroscler Thromb Vasc Biol. 1995;15:2122-2129.
72. Weintraub MS, Grosskopf I, Rassin T, Miller H, Charach G, Rotmensch HH, Liron M, Rubinstein A, Iaina A. Clearance of chylomicron remnants in normolipidaemic patients with coronary artery disease: case control study over three years. BMJ. 1996;312: 935-939.
73. Avogaro P, Bittolo Bon G, Cazzolato G, Rorai E. Relationship between apolipoproteins and chemical components of lipoproteins in survivors of myocardial infarction. Atherosclerosis. 1980;37:69-76.
74. Chung BH, Segrest JP. Resistance of a very low density lipoprotein subpopulation from familial dysbetalipoproteinemia to in vitro lipolytic conversion to the low density lipoprotein fraction. J Lipid Res. 1983;24:1148-1159.
75. Ehnholm C, Mahley RW, Chappell, Weisgraber KH, Ludwig E, Witztum JL. Role of apolipoprotein E in the lipolytic conversion of β-very low density lipoproteins to low density lipoproteins in type III hyperlipoproteinemia. Proc Natl Acad Sci U S A. 1984;81: 5566-5570.
76. Herz J, Willnow TE. Lipoprotein and receptor interactions in vivo. Curr Opin Lipidol. 1995;6:97-103.
77. Mahley RW, Innerarity TL, Rall SC, Weisgraber KH, Taylor JM. Apolipoprotein E genetic variants provide insights into its structure and function. Curr-Opin Lipidol. 1990;1:87-95.
78. Hamilton RL, Moorehouse A, Havel RJ. Isolation and properties of nascent lipoproteins from highly purified rat hepatocytic Golgi fractions. J Lipid Res. 1991;32:529-543.
79. Ishikawa Y, Fielding C, Fielding PE. A change in apolipoprotein B expression is required for the binding of apolipoprotein E to very low density lipoprotein. J Biol Chem. 1988;263:2744-2749.
80. Kandouss, A, Cachera C, Parsy D, Bard JM, Fruchar, JC. Quantitative determination of different apolipoprotein B containing lipoproteins by an enzyme linked immunosorbent assay: apoB with apoC-III and apoB with apoE. J Immunoassay. 1991;12:305-323.
81. Yang C-Y, Xie Y-H, Yang M, Quion JA, Gotto AM Jr. ELISA quantitation of apolipoproteins in plasma lipoprotein fractions: apoE in apoB-containing lipoproteins (Lp B:E) and apoB in apoE-containing lipoproteins (Lp E:B). J Protein Chem. 1995;14:503-509.
82. Genest JJ Jr, Bard JM, Fruchart J-C, Ordovas JM, Wilson PRW, Schaefer EJ. Plasma apolipoprotein A-I, A-II, B, E and C-III containing particles in men with premature coronary artery disease. Atherosclerosis. 1991;90:149-157.
83. Parra HJ, Arveiler D, Evans AE, Cambou JP, Amouyel P, Bingham A, McMaster D, Schaffer P, Douste-Blazy P, Luc G, Richard JL, Ducimetiere P, Fruchart JC, Cambien F. A case-control study of lipoprotein particles in two populations at contrasting risk for coronary heart disease: the ECTIM Study. Arterioscler Thromb. 1992; 12:701-707.
84. Alsayed N, Rebourcet R, Chapman J. Concentrations ot apoprotein CII CIII and E in total serum and in the apoprotein B-containing lipoproteins, determined by a new enzyme-linked immunosorbent assav. Clin Chem. 1990;36:2047-2052.
85. Blum CB, Aron L, Sciacca R. Radioimmunoassay studies of human apolipoprotein E. J Clin Invest. 1980;66:1240-1250.
86. Havel RJ, Kotite L, Vigne J-L, Kane JP, Tun P, Phillips N, Chen GC. Radioimmunoassay of human arginine-rich apolipoprotein, apoprotein E: concentration in blood plasma and lipoproteins as affected by apoprotein E-3 deficiency. J Clin Invest. 1980;66:1351-1362.
87. Falko JM, Schonfeld G, Witztum JL, Kolar JB, Weidman SW, Steelman R. Effects of diet on apolipoprotein E levels and on the apoprotein E subspecies in human plasma lipoproteins. J Clin Endocrinol Metab. 1980;50:521-528.
88. Milne RW, Doust-Blazy PH, Marcel YL, Retegui L. Characterization of monoclonal antibodies against human apolipoprotein E. J Clin Invest. 1981;68:111-117.
89. Gibson JC, Rubinstein A, Bukberg PR, Brown WV. Apolipoprotein E-enriched lipoprotein subclasses in normolipidemic subjects. J Lipid Res. 1983;24:886-898.
90. Rubinstein A, Gibson JC, Paterniti JR Jr, Kakis G, Little A, Ginsberg HN, Brown WV. Effect of heparin-induced lipolysis on the distribution of apolipoprotein E among lipoprotein subclasses: studies with patients deficient in hepatic triglyceride lipase and lipoprotein lipase. J Clin Invest. 1985;75:710-721.
91. Gibson JC, Rubinstein A, Brown WV, Ginsberg HN, Greten H, Norum R, Kayden H. ApoE-containing lipoproteins in low or high density lipoprotein deficiency. Arteriosclerosis. 1985;1985:371-380.
92. Gibson JC, Goldberg RB, Rubinstein A, Ginsberg HN, Brown WV, Baker S, Joffe BI, Seftel HC. Plasma lipoprotein distribution of apolipoprotein E in familial hypercholesterolemia. Arteriosclerosis. 1987;7:401-407.
93. Cohn JS, Tremblay M, Amiot M, Bouthillier D, Roy M, Genest J Jr, Davignon J. Plasma concentration of apolipoprotein E in intermediate-sized remnant-like lipoproteins in normolipidemic and hyperlipidemic subjects. Arterioscler Thromb Vasc Biol. 1996;16: 149-159.
94. Castro GR, Fielding CJ. Evidence for the distribution of apolipoprotein E between lipoprotein classes in human normocholesterolemic plasma and for the origin of unassociated apolipoprotein E (Lp-E). J Lipid Res. 1984;25:58-67.
95. Puchois P, Luley C, Alaupovic P. Comparison of four procedures for separating apolipoprotein A- and apolipoprotein B-containing lipoproteins in plasma. Clin Chem. 1987;33:1597-1602.
96. Luc G, Fievet C, Arveiler D, Evans AE, Bard J-M, Cambien F, Fruchart J-C, Ducimetiere P. Apolipoproteins C-III and E in apoB- and non-apoB-eontaining lipoproteins in two populations at contrasting risk for myocardial infarction: the ECTIM study: Etude Cas Temoins sur 'Infarctus du Myocarde. J Lipid Res. 1996;37:508-517.
97. Alaupovic P. Apolipoprotein composition as the basis for classifying plasma lipoproteins: characterization of ApoA- and ApoB-containing lipoprotein families. Prog Lipid Res. 1991;30:105-138.
98. Alaupovic P, Knight-Gibson C, Wang C-S, Downs D, Koren E, Brewer HB Jr, Gregg RE. Isolation and characterization of an apoA-II-containing lipoprotein (LP-A-II:B complex) from plasma very low density lipoproteins of patients with Tangier disease and type V hyperlipoproteinemia. J Lipid Res. 1991;32:9-19.
99. Koren E, Alaupovic P, Lee DM, Dashti N, Kloer HU, Wen G. Selective isolation of human plasma low-density lipoprotein particles containing apolipoproteins B and E by use of a monoclonal antibody to apolipoprotein B. Biochemistry. 1987;26:2734-2740.
100. Bard JM, Candelier L, Agnani G, Clavey V, Torpier G, Steinmetz A, Fruchart JC. Isolation and characterization of human Lp-B lipoprotein containing apolipoprotein B as the sole apolipoprotein. Biochim Biophys Acta. 1991;1082:170-176.
101. Alaupovic P, Blackenhorn DH, Knight-Gibson C, Tavella M, Bard J-M, Shafer D, Lee ET, Brasuell J. ApoB-containing lipoprotein particles as risk factors for coronary artery disease. Adv Exp Med Biol. 1990;285:299-309.
102. Koren E, Corder C, Mueller G, Centurion H, Hallum G, Fesmire J, McConathy WD. Alaupovic P. Triglyceride enriched lipoprotein particles correlate with the severity of coronary artery disease. Atherosclerosis. 1996;122:105-115.
103. Alaupovic P, Mack WJ, Knight-Gibson C, Hodis HN. The role of triglyceride-rich lipoprotein families in the progression of atherosclerotic lesions as determined by sequential coronary angiography from a controlled clinical trial. Arterioscler Thromb Vasc Biol. 1997;17:715-722.
104. Schaefer EJ, Gregg RE, Ghiselli G, Forte TM, Ordovas JM, Zech LA, Brewer HB Jr. Familial apolipoprotein E deficiency. J Clin Invest. 1986;78:1206-1219.
105. Zhang SH, Reddick RL, Pierdrahita JA, Maeda N. Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science. 1992;258:468-471.
106. Plump AS, Smith JD, Hayek T, Aalto-Setala K, Walsh A, Verstuyft JG, Rubin EM, Breslow JL. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell. 1992;71:343-353.
107. Hofker MH, van Vlijmen BJM, Havekes LM. Transgenic mouse models to study the role of APOE in hyperlipidemia and atherosclerosis. Atherosclerosis. 1998;137:1-11.
108. Nakashima Y, Plump AS, Raines EW, Breslow JL, Ross R. ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree. Arterioscler Thromb. 1994;14:133-140.
109. Reddick RL, Zhang SH, Maeda N. Atherosclerosis in mice lacking apoE: evaluation of lesional development and progression. Arterioscler Thromb. 1994;14:141-147.
110. Mazzone T. Apolipoprotein E secretion by macrophages: its potential physiological functions. Curr Opin Lipidol. 1996;7: 303-307.
111. Von Eckardstein A. Cholesterol efflux from macrophages and other cells. Curr Opin Lipidol. 1996;7:308-319.
112. Palinski W, Ord VA, Plump AS, Breslow JL, Stemberg D, Witztum JL. ApoE-deficient mice are a model of lipoprotein oxidation in atherogenesis: demonstration of oxidation-specific epitopes in lesions and high liters of autoantihodies to malondialdehyde-lysine in serum. Arterioscler Thromb. 1994;14:605-616.
113. Pratico D, Tangirala RK, Rader DJ, Rokach J, Fitzgerald GA. Vitamin E suppresses isoprostane generation in vivo and reduces atherosclerosis in apoE-deficicnt mice. Nat Med. 1998;4:1189-1192.
114. Hayek T, Attias J, Smith J, Breslow JL, Keidar S. Antiatherosclerotic and antioxidative effects of captopril in apolipoprotein E-deficient mice. J Cardiovasc Pharmacol. 1998;31:540-544.
115. Alaupovic P. David Rubinstein Memorial Lecture: the biochemical and clinical significance of the interrelationship between very low density and high density lipoproteins. Can J Biochem. 1981;59: 565-579.
116. Schonfeld G, George PK, Miller J, Reilly P, Witztum J. Apolipoprotein C-II and C-III levels in hyperlipoproteinemia. Metabolism. 1979;28:1001-1010.
117. Curry MD, McConathy WJ, Fesmire JD, Alaupovic P. Quantitative determination of human apolipoprotein C-III by electroimmunoassay. Biochim Biophys Acta. 1980;617:503-513.
118. Kashyap ML, Srivastava LS, Hynd BA, Gartside PS, Perisutti G. Quantitation of human apolipoprotein C-III and its subspecies by radioimmunoassay and analytical isoelectric focusing: abnormal plasma triglyceride-rich lipoprotein C-III subspecies concentrations in hypertriglyceridemia. J Lipid Res. 1981;22:800-810.
119. Brown WV, Baginsky ML. Inhibition of lipoprotein lipase by an apoprotein of human very low density lipoprotein. Biochem Biophys Res Commun. 1972;46:375-382.
120. Wang CS, McConathy WJ, Kloer HU, Alaupovic P. Modulation of lipoprotein lipase activity by apolipoproteins: effect of apolipoprotein C-III. J Clin Invest. 1985;75:383-390.
121. Ginsberg HN, Le N-A, Goldberg IJ, Gibson JC, Rubinstein A, Wang-Iverson P, Norum R, Brown WV. Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI: evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo. J Clin Invest. 1986;78:1287-1295.
122. Shelburne F, Hanks J, Meyers W, Quarfordt SA. Effect of apoproteins on hepatic uptake of triglyceride emulsions in the rat. J Clin Invest. 1980;65:652-658.
123. Windier E, Havel RJ. Inhibitory effects of C apolipoproteins from rats and humans on the uptake of triglyceride-rich lipoproteins and their remnants by the perfused rat liver. J Lipid Res. 1985;26: 556-563.
124. Kowal RC, Herz J, Weisgraber KH, Mahley RW, Brown MS, Goldstein JL. Opposing effects of apolipoproteins E and C on lipoprotein binding to low density lipoprotein receptor-related protein. J Biol Chem. 1990;265:10771-10779.
125. Clavey V, Lestavel-Delattre S, Copin C, Bard JM, Fruchart JC. Modulation of lipoprotein B binding to the LDL receptor by exogenous lipids and apolipoproteins CI, CII, CIII, and E. Arterioscler Thromb Vasc Biol. 1995;15:963-971.
126. Kinnunen PKJ, Ehnholm C. Effect of serum and C apoproteins from very low density lipoproteins on human postheparin plasma hepatic lipase. FEBS Lett. 1976;65:354-357.
127. Hegele RA, Little JA, Vezina C, Maguire GF, Tu L, Wolever TS, Jenkins DJA, Connelly PW. Hepatic lipase deficiency: clinical, biochemical and molecular genetic characteristics. Arterioscler Thromb. 1993;3:720-728.
128. Graziani MS, Zanolla L, Righetti G, Marchetti C, Zanotto G, Lupo A. Distribution of CII and CIII peptides in lipoprotein classes: methods and clinical significance. Clin Chem. 1994;40:240-244.
129. Fredenrich A, Giroux L-M, Tremblay M, Krimbou L, Davignon J, Cohn JS. Plasma lipoprotein distribution of apoC-III in normolipidemic and hyperlipidemic subjects: comparison of the apoC-III to apoE ratio in different lipoprotein fractions. J Lipid Res. 1997;38: 1421-1432.
130. Blankenhorn DH, Alaupovic P, Wickham E, Chin HP, Azen SP. Prediction of angiographic change in native human coronary arteries and aortocoronary bypass grafts: lipid and nonlipid factors. Circulation. 1990;81:470-476.
131. Hodis HN, Mack WJ, Azen SP, Alaupovic P, Pogoda JM, LaBree L, Hemphill LC, Kramsch DM, Blankenhorn DH. Triglyceride- and cholesterol-rich lipoproteins have a differential effect on mild/ moderate and severe lesion progression as assessed by quantitative coronary angiography in a controlled trial of lovastatin. Circulation. 1994;90:42-49.
132. Blankenhorn DH, Selzer RH, Crawford DW, Barth JD, Liu C-r. Liu C-h, Mack WJ, Alaupovic P. Beneficial effects of colestipol-macin therapy on the common carotid artery: two- and four-year reduction of intima-media thickness measured by ultrasound. Circulation. 1993;88:20-28.
133. Hodis HN, Mack WJ, LaBree L, Selzer RH, Liu C, Liu C, Alaupovic P, Kwong-Fu H, Azen SP. Reduction in carotid arterial wall thickness using lovastatin and dietary therapy: a randomized, controlled clinical trial. Ann Intern Med. 1996;124:548-556.
134. Ebara T, Ramakrishnan R, Steiner G, Shachter NS. Chylomicronemia due to apolipoprotein CIII overexpression in apolipoprotein E-null mice: apolipoprotein CIII-induced hypertriglyceridemia is not mediated by effects on apolipoprotein E. J Clin Invest. 1997;99:2672-2681.
135. Hayek T, Masucci-Magoulas L, Jiang X, Walsh A, Rubin E, Breslow JL, Tall AR. Decreased early atherosclerotic lesions in hypertriglyceridemic mice expressing cholesteryl ester transfer protein transgene. J Clin Invest. 1995;96:2071-2074.
136. Masucci-Magoulas L, Goldberg U, Bisgaier CL, Serajuddm H, Francone OL, Breslow JL, Tall AR. A mouse model with features of familial combined hyperlipidemia. Science. 1997;275:391-394.
137. Havel RJ. Postprandial hyperlipidemia and remnant lipoproteins. Curr Opin Lipidol. 1994;5:102-109.
138. Edge SB, Hoeg JM, Schneider PD, Brewer HB Jr. Apolipoprotein B synthesis in humans: liver synthesizes only apolipoprotein B-100. Metabolism. 1985;34:726-730.
139. Simons LA, Dwyer T, Simons J, Bernstein L, Mock P, Pooma NS, Balasubramaniam S, Baron D, Branson J, Morgan J, Roy P, Chylomicrons and chylomicron remnants in coronary artery disease: a case-control study. Atherosclerosis. 1987;65:181-189.
140. Kotite L, Bergeron N, Havel RJ. Quantification of apolipoproteins B-100, B-48, and E in human triglyceride-rich lipoproteins. J Lipid Res. 1995;36:890-900.
141. Lovegrove JA, Isherwood SG, Jackson KG, Williams CM, Gould BJ. Quantitation of apolipoprotein B-48 in triacylglycerol-rich lipoproteins by a specific enzyme-linked immunosorbent assay. Biochim Biophys Acta. 1996;1301:221-229.
142. Cohn JS, McNamara JR, Conn SD, Ordovas JM, Schaefer EJ. Plasma apolipoprotein changes in the triglyceride-rich lipoprotein fraction of human subjects fed a fat-rich meal. J Lipid Res. 1988;29:925-936.
143. Schneeman BO, Kotite L, Todd K, Havel RJ. Relationship between the responses of triglyceride-rich lipoproteins in blood plasma containing apolipoproteins B-48 and B-100 to a fat-containing meal in normolipidemic humans. Proc Natl Acad Sci U S A. 1993;90: 2069-2073.
144. Karpe F, Steiner G, Olivecrona T, Carlson LA, Hamsten A. Metabolism of triglyceride-rich lipoproteins during alimentary lipemia. J Clin Invest 1993;91:748-758.
145. Patsch JR, Miesenböck G, Hopferwieser T, Mühlgerger V, Knapp E, Dunn JK, Gotto AM Jr, Patsch W. Relation of triglyceride metabolism and coronary artery disease: studies in the postprandial state. Arterioscler Thromb. 1992;12:1336-1345.
146. Karpe F, Steiner G, Uffelman K, Olivecrona T, Hamsten A. Postprandial lipoproteins and progression of coronary atherosclerosis. Atherosclerosis. 1994;106:83-97.
147. Nakajima K, Saito T, Tamura A, Suzuki M, Nakano T, Adachi M, Tanaka A, Tada N, Nakamura H, Campos E, Havel RJ. Cholesterol in remnant-like lipoproteins in human serum using monoclonal anti apo B-100 and anti apo A-I immunoaffinity mixed gels. Clin Chim Acta. 1993;223:53-71.
148. Nakajima K, Okazaki M, Tanaka A, Pullinger CR, Wang T, Nakano T, Adachi M, Havel RJ. Separation and determination of remnant-like particles in human serum using monoclonal antibodies to apoB-100 and apo AI. J Clin Ligand Assay. 1996;19:177-183.
149. Marcoux C, Tremblay M, Jacques H, Krimbou L, Fredenrich A, Nakajima K, Davignon J, Cohn JS. Plasma remnant-like particle lipid and apolipoprotein levels in normolipidemic and hyperlipidemic subjects. Atherosclerosis. 1998;139:161-171.
150. McNamara JR, Shah PK, Nakajima K, Cupples LA, Wilson PWF, Ordovas JM, Schaefer EJ. Remnant lipoprotein cholesterol and triglyceride reference ranges
151. Leary ET, Wang T, Baker DJ, Cilla DD, Zhong J, Warnick GR, Nakajima K, Havel RJ. Evaluation of an immunoseparation method for quantitative measurement of remnant-like particle-cholesterol in serum and plasma. Clin Chem. 1998;44:2490-2498.
152. Ikewaki K, Shige H, Nakajima K, Nakamura H. Postprandial remnant-like particles and coronary artery disease. In: Woodford FP, Davignon J, Sniderman A, eds. Atherosclerosis X. Amsterdam, Netherlands: Elsevier; 1995:200-202.
153. Tanaka A, Tomie N, Nakano T, Nakajima K, Yui K, Tamura M, Numano F. Measurement of postprandial remnant-like particles (RLP) following a fat-loading test. Clin Chim Acta. 1998;275:43-52.
154. Shimizu H, Mori M, Sato T. An increase of serum remnant-like particles in noninsulin-dependent diabetic patients with microalbuminuria. Clin Chim Acta. 1993;221:191-196.
155. Nakajima K, Saito T, Tamura A, Suzuki M, Nakano T, Adachi M, Tanaka A, Tada N, Nakamura H, Murase T. A new approach for the detection of type III hyperlipoprpteinemia by RLP-cholesterol assay. J Atheroscler Thromb. 1994;4:30-36.
156. Sekihara T, Nakano T, Nakajima K. High postprandial plasma remnant-like particles-cholesterol in patients with coronary artery diseases on chronic maintenance hemodialysis. Jpn J Nephrol. 1996; 38:220-228.
157. Oda H, Yorioka N, Okushin S, Nishida Y, Kushihata S, Ito T, Yamakido M. Remnant-like particles cholesterol may indicate atherogenic risk in patients on chronic hemodialysis. Nephron. 1997; 76:7-14.
158. Tanaka A, Ejiri N, Fujinuma Y, Yui K, Tamura M, Nakajima K, Morohoshi M, Fujisawa K, Uchimura I, Numano F. Remnant-like particles and restenosis of coronary arteries after PTCA. Ann N Y Acad Sci. 1995;748:595-598.
159. Nakamura H, Ikewaki K, Nishiwaki M, Shige H. Postprandial hyperlipidemia and coronary artery disease. Ann N Y Acad Sci. 1995; 748:441-446.
160. McNamara JR, Shah PK, Nelson SM, Nakajima K, Wilson PWF, Schaefer EJ. Lipoprotein remnant cholesterol and triglyceride values in coronary cases and Framingham controls. Circulation. 1996; 94(suppl I):I-94. Abstract.
161. Devaraj S, Vega G, Lange R, Grundy SM, Jialal I. Remnant-like particle cholesterol levels in patients with dysbetalipoproteinemia or coronary artery disease. Am J Med. 1998;104:445-450.
162. Takeichi S, Nakajima Y, Osawa M, Yukawa N, Saito T, Seto Y, Nakano T, Adachi M, Jitsukata K, Horiuchi K, Wang T, Nakajima K. The possible role of remnant-like particles as a risk factor for sudden cardiac death. Int J Legal Med. 1997;110:213-219.
163. Tomono S, Kawazu S, Kato N, Ono T, Ishii C, Ito Y, Shimizu M, Shimoyama M, Nakano T, Nakajima K. Uptake of remnant like particles (RLP) in diabetic patients from mouse peritoneal macrophages. J Atheroscler Thromb. 1994;1:98-102.
164. Knöfler R, Nakano T, Nakajima K, Takada Y, Takada A. Remnant-like lipoproteins stimulate whole blood platelet aggregation in vitro. Thromb Res. 1995;78:161-171.
165. Mochizuki M, Takada TY, Urano T, Nagai N, Nakano T, Nakajima K, Tanaka A. The in vivo effects of chylomicron remnant and very low density lipoprotein remnant on platelet aggregation in blood obtained from healthy persons. Thromb Res. 1996;5:583-593.
166. Kugiyama K, Doi H, Motoyama T, Soejima H, Misumi K, Kawano H, Ohta Y, Nakagawa O, Yoshimura M, Ogawa H, Matsumura T, Sugiyama S, Nakano T, Nakajima K, Yasue H. Association of remnant lipoprotein levels with impairment of endothelium-dependent vasomotor function in human coronary arteries. Circulation. 1998;97:2519-2526.
167. Campos E, Nakajima K, Tanaka A, Havel RJ. Properties of an apolipoprotein E-enriched fraction of triglyceride-rich lipoproteins isolated from human blood plasma with a monoclonal antibody to apolipoprotein B-100. J Lipid Res. 1992;33:369-380.
168. Marcoux C, Tremblay M, Nakajima K, Davignon J, Cohn JS. Characterization of remnant-like particles isolated by immunoaffinity gel from the plasma of type III and type IV hyperlipoproteinemic patients. J Lipid Res. 1999;40:636-647.
169. Karpe F, Bond GM, Hamsten A. Remnant-like lipoproteins concentration in plasma is strongly associated with early signs of carotid atherosclerosis in healthy 50-year old men. Circulation. 1998; 98(suppl I):I-451. Abstract.
170. Williams KJ, Tabas I. The response-to-retention hypothesis of early atherogenesis. Arterioscler Thromb Vasc Biol. 1995;15:551-561.
171. Nordestgaard BG, Tybjaerg-Hansen A, Lewis B. Influx in vivo of low density, intermediate density, and very low density lipoproteins into aortic intimas of genetically hyperlipidemic rabbits: roles of plasma concentration, extent of aortic lesion, and lipoprotein particle size as determinants. Arterioscler Thromb. 1992;12:6-18.
172. Nordestgaard BG, Zilversmit DB. Large lipoproteins are excluded from the arterial wall in diabetic cholesterol-fed rabbits. J Lipid Res. 1988;29:1491-1500.
173. Nordestgaard BG, Wootton R, Lewis B. Selective retention of VLDL, IDL, and LDL in the arterial intima of genetically hyperlipidemic rabbits in vivo: molecular size as a determinant of fractional loss from the intima-inner media. Arterioscler Thromb Vasc Biol. 1995;5:534-542.
174. Poapst M, Reardon M, Steiner G. Relative contribution of triglyceride-rich lipoprotein particle size and number to plasma triglyceride concentration. Arteriosclerosis. 1985;5:381-390.
175. Steiner G, Tkac I, Uffelman KD, Lewis GF. Important contribution of lipoprotein particle number to plasma triglyceride concentration in type 2 diabetes. Atherosclerosis. 1998;137:211-214.
176. Davignon J, Cohn JS, Mabile L, Bernier L. Apolipoprotein E and atherosclerosis: insights from animal and human studies. Clin Chim Acta. In press.
177. Hendriks WL, van der Sman-de Beer F, van Vlijmen BJ, van Vark LC, Hofker MH, Havekes LM. Uptake by J774 macrophages of very-low-density lipoproteins isolated from apoE-deficient mice is mediated by a distinct receptor and stimulated by lipoprotein lipase. Arterioscler Thromb Vasc Biol. 1997;17:498-504.
178. Hakamata H, Sakaguchi H, Zhang C, Sakashita N, Suzuki H, Miyazaki A, Takeya M, Takahashi K, Kitamura N, Horiuchi S. The very low- and intermediate-density lipoprotein fraction isolated from apolipoprotein E-knockout mice transforms macrophages to foam cells through an apolipoprotein E-dependent pathway. Biochemistry. 1998;37:13720-13727.
179. Gianturco SH, Ramprasad MP, Lin AH-Y, Song R, Bradley WA. Cellular binding site and membrane binding proteins for triglyceride-rich lipoproteins in human monocyte-macrophages and THP-1 monocytic cells. J Lipid Res. 1994;35:1674-1687.
180. Ramprasad MP, Li R, Bradley WA, Gianturco SH, Human THP-1 monocyte-macrophage membrane binding proteins: distinct receptor(s) for triglyceride-rich lipoproteins. Biochemistry. 1995;34: 9126-9135.
181. Whitman SC, Sawyez CG, Miller DB, Wolfe BM, Huff MW. Oxidized type IV hypertriglyceridemic VLDL-remnants cause greater macrophage cholesteryl ester accumulation than oxidized LDL. J Lipid Res. 1998;39:1008-1020.
182. Palinski W, Hörkkö S, Miller E, Steinbrecher UP, Powell HC, Curtiss LK, Witztum JL. Cloning of monoclonal autoantibodies to epitopes of oxidized lipoproteins from apolipoprotein E-deficient mice: demonstration of epitopes of oxidized low density lipoprotein in human plasma. J Clin Invest. 1996;98:800-814.
183. Staprans I, Rapp JH, Pan X-M, Feingold KR. The effect of oxidized lipid in the diet on serum lipoprotein peroxides in control and diabetic rats. J Clin Invest. 1993;92:638-643.
184. Staprans I, Rapp JH, Pan X-M, Kim KY, Feingold KR. Oxidized lipids in the diet are a source of oxidized lipid in chylomicrons of human serum. Arterioscler Thromb. 1994;14:1900-1905.
185. Staprans I, Rapp JH, Pan X-M, Hardman DA, Feingold KR. Oxidized lipids in the diet accelerate the development of fatty streaks in cholesterol-fed rabbits. Arterioscler Thromb Vasc Biol. 1996;16:533-538.